MAXMIND Bio-Technology

Maxmind Biotech is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the discovery and development of innovative small molecule therapeutics. The company utilizes a proprietary structure-based drug design platform to target high-value pathways in oncology, metabolic diseases, and autoimmune disorders. Its lead candidate, MXD-1108, is a potent and selective URAT1 inhibitor currently in Phase 2 clinical trials for the treatment of gout and hyperuricemia. Maxmind aims to deliver best-in-class or first-in-class medicines by optimizing chemical structures to improve safety, efficacy, and patient outcomes.